Vaxdyn is a Spanish biotech headquartered in Seville that develops preventive vaccines against antimicrobial-resistant Gram-negative bacteria, including Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa and pathogenic Escherichia coli - pathogens ranked among the most critical threats by the WHO. Building on a proprietary vaccine platform, the company is advancing a multi-pathogen pipeline whose lead candidate, K-VAX, is being prepared for a first-in-human Phase 1 trial against K. pneumoniae and A. baumannii. Vaxdyn was the first Spanish biotech funded by CARB-X, the global public-private partnership for early-stage antibacterial development.
1
Round
1
Industry
4
Tags
Sep 7, 2026
Latest raise
Funding activity · 1 round
Sep 7, 2026
EUR 11M
Series A
Led by Biovance Capital
Vaxdyn Raises €11 Million Series A Led by Biovance Capital Seville based biotech Vaxdyn has secured €11,000,000 in a Series A round. The funding was announced…
Read articlePricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
